- Conditions
- Chronic Pruritus of Unknown Origin
- Interventions
- Remibrutinib, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Brighton, Massachusetts • Clarkston, Michigan + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 73
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atopic Dermatitis
- Interventions
- Tradipitant, Placebo
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 51
- States / cities
- Hoover, Alabama • Tempe, Arizona • Encino, California + 43 more
- Conditions
- Pruritus
- Interventions
- 5 mg Serlopitant Tablets, Matching Placebo Tablets
- Drug
- Lead sponsor
- Vyne Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 41
- States / cities
- Hot Springs, Arkansas • Bakersfield, California • Fremont, California + 36 more
- Conditions
- Moderate to Severe Chronic Plaque-type Psoriasis
- Interventions
- secukinumab low dose, secukinumab high dose
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 4
- States / cities
- Fountain Valley, California • Jacksonville, Florida • Lebanon, New Hampshire + 1 more
- Conditions
- Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)
- Interventions
- CLE-400, Vehicle
- Drug
- Lead sponsor
- Clexio Biosciences Ltd.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 13
- States / cities
- Bryant, Arkansas • Fremont, California • Coral Gables, Florida + 10 more
- Conditions
- Psoriasis Vulgaris, Psoriasis
- Interventions
- tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g, placebo ointment (vehicle)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 476 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 29
- States / cities
- Hot Springs, Arkansas • Bakersfield, California • Irvine, California + 22 more
- Conditions
- Burn, Chronic Pain Following Thermal Burn Injury, Non-Pharmacological Interventions, Virtual Reality, Sleep Disturbance, Anxiety, Depressive Symptoms, Fatigue Symptom, Pruritus, Burn Injury, Progressive Muscle Relaxation
- Interventions
- Virtual Reality-Enhanced Progressive Muscle Relaxation, Standard Progressive Muscle Relaxation
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Benralizumab, Placebo and Benralizumab
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more
- Conditions
- Psoriasis
- Interventions
- CP-690,550, Placebo/CP-690,550
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Bakersfield, California + 33 more
- Conditions
- Pruritis
- Interventions
- 50,000 Units Ergocalciferol, Placebo
- Drug
- Lead sponsor
- Winthrop University Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Bethpage, New York • Mineola, New York
- Conditions
- Plaque-type Psoriasis
- Interventions
- Placebo, Secukinumab 150mg, Secukinumab 300mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Ligelizumab, Omalizumab, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,078 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more
- Conditions
- Chronic Pruritus
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Ligelizumab, Omalizumab, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,072 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 30
- States / cities
- Gilbert, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 26 more
- Conditions
- Uremic Pruritus
- Interventions
- CR845 0.5 mcg/kg, Placebo
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 57
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Bakersfield, California + 52 more
- Conditions
- Psoriasis
- Interventions
- CP-690,550
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 50
- States / cities
- Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more
- Conditions
- Vitamin D Deficiency, End Stage Renal Disease
- Interventions
- Not listed
- Lead sponsor
- Winthrop University Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Mineola, New York
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Briquilimab, Placebo
- Drug · Other
- Lead sponsor
- Jasper Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more
- Conditions
- Chronic Kidney Diseases, Pruritus
- Interventions
- CR845 0.25 mg Oral Tablet, CR845 0.5 mg Oral Tablet, CR845 1 mg Oral Tablet, Placebo Oral Tablet
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Florence, Alabama • Phoenix, Arizona + 52 more
- Conditions
- Cutaneous Nerves CNS Itch
- Interventions
- Clonidine, Naltrexone
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 12 more
- Conditions
- Uremic Pruritus
- Interventions
- CR845 0.5 mcg/kg
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 33
- States / cities
- Escondido, California • Riverside, California • San Diego, California + 26 more
- Conditions
- Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
- Interventions
- KPL-716, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more
- Conditions
- Prurigo Nodularis
- Interventions
- INCB054707, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Sacramento, California + 19 more